Biotechnology company Imviva Biotech is set to present data on its CAR-T pipeline at the American Society of Haematology (ASH) Annual Meeting. 

Imviva will reveal progress in allogeneic cell therapy candidates being developed for multiple haematological conditions, including T-cell acute lymphoblastic leukaemia, lymphoblastic lymphoma, acute myeloid leukaemia, B-cell acute lymphoblastic leukaemia and severe aplastic anaemia. 

“We will share the breadth and depth of our ANSWER platform, which addresses many limitations encountered by autologous and allogeneic CAR-T cell therapy,” said Imviva Biotech Chief Medical Officer Jan Davidson-Moncada.  

“This will include the breakthrough progress of our lead investigational product, CTD402, in treating leukaemias.  

“Two oral presentations will highlight the favourable safety and efficacy of CTD402 in patients with relapsed/refractory T-ALL/LBL and CD7+ AML, challenging haematological cancers with limited treatment options leading to high mortality.  

This data further validates the potential of our CD7 targeting strategy and our allogeneic cell platform, and we remain committed to bringing these innovative therapies to patients worldwide who urgently need better treatment options as soon as possible.” 

The ASH annual meeting begins on 6 December and ends on 9 December.

 

Bruno Quinney, Content Team, DDW